One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial

Stefanie Schulz1*, MD; Adnan Kastrati1, MD; Miroslaw Ferenc2, MD; Steffen Massberg1, MD; Kathrin A. Birkmeier1, MD; Karl-Ludwig Laugwitz3, MD; Sebastian Kufner1, MD; Michael Gick2, MD; Michael Dommasch1, MD; Helmut Schühlen4, MD; Albert Schömig1,3, MD; Peter B. Berger5, MD; Julinda Mehilli1, MD; Franz-Josef Neumann2, MD; for the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 4 Trial Investigators